Web Results


Jun 2, 2010 ... Biogen Idec Inc. has accused pharmaceutical heavyweights Bayer AG, Novartis AG, Pfizer Inc. and Merck KGaA unit EMD Serono Inc. of infringing a ... Biogen Sues Bayer, Others Over Multiple Sclerosis Drug ... EMD Serono et al., case number 10-cv-02760, and Bayer Healthcare Pharmaceuticals Inc. v.


Sincerely,. James E. Hoyes. President and Head of US Operations. EMD Serono, Inc. Message from James E. Hoyes, President, EMD Serono, Inc. ... with health care organizations and specialty pharmacies to develop mutually effective solutions to address the needs of today while ..... Blaser DA, Lewtas AJ, et al. How to ...


Oct 23, 2017 ... EMD Serono, Inc. is a recognized leader in the biopharmaceutical industry, with more than 1100 employees throughout the United States. Our headquarters are in Rockland, MA. EMD Serono is an affiliate of Merck KGaA, Darmstadt, Germany .


Jul 8, 2009 ... Pamela S. Chestek. Commentary: Persistent Infirmities in Trademark Priority: Toward a Cure ... Association in. Magasins Best Buy Ltée et al. v. Office Québécois de la Langue Française. Amicus Brief of the International Trademark Association in. Lexmark International, Inc. v. Static Control Components, Inc.


Mar 26, 2004 ... Axel Patent Litigation, e.g., Genentech, Inc. v. Tr. of .... See Angel Pellicer et al., Altering Genotype and Phenotype by DNA-Mediated Gene ..... Corp. v. Tr. of Columbia Univ. (D. Mass. 2003) (No. 03-cv-12221-MLW) [hereinafter. “Baxter Complaint”]; Complaint at ¶ 7, Serono, Inc. v. Tr. of Columbia Univ.


The rapidly expanding biologics segment is projected to account for about 20% of the global drug market by 2017. Today, many of the top health care expenditure drugs are biologics, e.g., infliximab (Remicade, Janssen), rituximab ( Rituxan, Genentech, Inc./Biogen Idec Inc.), bevacizumab (Avastin, Genentech, Inc.), ...


Jul 9, 2014 ... Over the past decade, numerous risk-minimization programs have been implemented and evaluated for a range of drug products across multiple .... Principles of 'evaluability,' which assess the likelihood that a program can be taken to scale, should also be incorporated during the design process [45].


As a chronic disease requiring lifelong treatment, most health plans now position RA drugs as a high-priority therapeutic category. .... Most (80%) payers in the survey reported they use specialty pharmacies for distribution of biologic therapies for RA. Among those who use .... Myasoedova E, Crowson CS, Kremers HM, et al.


Innovative Medicines Canada represents. Canada's innovative pharmaceutical industry. Our members make significant contributions to the country's economy through its R&D investments, the creation of high value jobs and support for homegrown startups, while providing funding for patient support programs, medical ...